trending Market Intelligence /marketintelligence/en/news-insights/trending/QJr8Ro_sBGO3pY1SQ_gFgQ2 content esgSubNav
In This List

Medtronic acquires spinal cord therapy company Stimgenics

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Medtronic acquires spinal cord therapy company Stimgenics

Medtronic PLC said it acquired Stimgenics LLC, a Bloomington, Ill.-based privately held company developing a spinal cord stimulation therapy.

Financial terms of the deal were not disclosed in a Jan. 8 news release.

Stimgenics offers a spinal cord stimulation waveform known as Differential Target Multiplexed spinal cord stimulation. The therapy is delivered through Medtronic's Intellis platform for treating patients with chronic pain.

Dublin-based medical device company Medtronic said the acquisition is expected to be neutral to the company's fiscal 2020 EPS.